Equities Analysts Offer Predictions for biote Q1 Earnings

biote Corp. (NASDAQ:BTMD) – Equities research analysts at Roth Capital lowered their Q1 2025 earnings per share estimates for shares of biote in a research note issued to investors on Thursday, March 13th. Roth Capital analyst G. Kelly now expects that the company will post earnings per share of $0.09 for the quarter, down from their prior estimate of $0.13. The consensus estimate for biote’s current full-year earnings is $0.75 per share. Roth Capital also issued estimates for biote’s Q2 2025 earnings at $0.12 EPS, Q3 2025 earnings at $0.15 EPS, Q4 2025 earnings at $0.16 EPS, FY2025 earnings at $0.53 EPS and FY2026 earnings at $0.70 EPS.

Separately, Craig Hallum reduced their price objective on biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday.

biote Trading Up 22.5 %

Shares of NASDAQ:BTMD opened at $3.76 on Friday. The stock’s 50-day moving average price is $4.96 and its two-hundred day moving average price is $5.55. biote has a 12-month low of $3.04 and a 12-month high of $8.44. The firm has a market cap of $204.31 million, a price-to-earnings ratio of 14.46 and a beta of 1.07.

Hedge Funds Weigh In On biote

Several hedge funds and other institutional investors have recently modified their holdings of BTMD. Price T Rowe Associates Inc. MD acquired a new position in shares of biote in the 4th quarter valued at about $67,000. Commonwealth Equity Services LLC acquired a new position in shares of biote in the 4th quarter valued at about $68,000. Public Employees Retirement System of Ohio acquired a new position in shares of biote in the 4th quarter valued at about $69,000. Intech Investment Management LLC acquired a new position in shares of biote in the 4th quarter valued at about $71,000. Finally, SG Americas Securities LLC acquired a new position in shares of biote in the 4th quarter valued at about $76,000. 21.68% of the stock is owned by institutional investors and hedge funds.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.